S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The 3-Stock Retirement Blueprint (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:GLPG

Galapagos - GLPG Stock Forecast, Price & News

$40.07
+0.30 (+0.75%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$39.70
▼
$40.30
50-Day Range
$39.14
▼
$46.51
52-Week Range
$38.97
▼
$72.11
Volume
114,165 shs
Average Volume
262,545 shs
Market Capitalization
$2.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.83

Galapagos MarketRank™ Forecast

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
39.3% Upside
$55.83 Price Target
Short Interest
Bearish
1.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Galapagos in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.40) to ($3.66) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

948th out of 1,047 stocks

Pharmaceutical Preparations Industry

461st out of 512 stocks

See Top Rated MarketRank™ Stocks Here
GLPG stock logo

About Galapagos (NASDAQ:GLPG) Stock

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

GLPG Stock News Headlines

November 29, 2022 | americanbankingnews.com
Brokerages Set Galapagos NV (NASDAQ:GLPG) Price Target at $55.83
November 10, 2022 | tmcnet.com
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
November 2, 2022 | finance.yahoo.com
Strong week for Galapagos (AMS:GLPG) shareholders doesn't alleviate pain of three-year loss
October 26, 2022 | finance.yahoo.com
Galapagos NV (GLPG.AS)
October 19, 2022 | wsj.com
Galapagos N.V. ADR
October 17, 2022 | globenewswire.com
Galapagos to host its R&D Update 2022 in New York on 4 November 2022 - GlobeNewswire
October 17, 2022 | finance.yahoo.com
Galapagos to host its R&D Update 2022 in New York on 4 November 2022
October 16, 2022 | reuters.com
Quake strikes in Pacific off Central America, no reports of damage - Reuters
October 15, 2022 | reuters.com
GLPG.AS - Galapagos NV | Stock Price & Latest News | Reuters
October 15, 2022 | markets.businessinsider.com
Expert Ratings for Galapagos
October 13, 2022 | benzinga.com
Expert Ratings for Galapagos - Galapagos (NASDAQ:GLPG) - Benzinga
October 10, 2022 | seekingalpha.com
Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product (NASDAQ:GLPG) - Seeking Alpha
October 9, 2022 | forbes.com
Scenic And Uncrowded Fall, Nepal To The Galapagos: Trek, Glamp, Bike, RV - Forbes
October 8, 2022 | nasdaq.com
Galapagos NV - ADR Shares Close in on 52-Week Low - Market Mover - Nasdaq
October 6, 2022 | globenewswire.com
Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress - GlobeNewswire
October 6, 2022 | finance.yahoo.com
Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
October 6, 2022 | usatoday.com
A fly threatens Galapagos archipelago - USA TODAY
October 4, 2022 | benzinga.com
Galapagos Receives Committee For Medicinal Products For Human Use Opinion For Jyseleca European Label Upd - Benzinga
October 3, 2022 | globenewswire.com
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies - GlobeNewswire
October 3, 2022 | finance.yahoo.com
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
October 2, 2022 | barrons.com
Galapagos Tortoise, Iguana Traffickers Jailed For One Year - Barron's
September 27, 2022 | nytimes.com
China’s Huge Appetite for Fish - The New York Times
September 27, 2022 | nypost.com
4 dead, including American, after tourist boat sinks near Galapagos Islands - New York Post
September 27, 2022 | abcnews.go.com
4 dead after tourist boat sinks near Galapagos Islands - ABC News
September 26, 2022 | nytimes.com
China's Fishing Operations Raise Alarms Worldwide - The New York Times
See More Headlines
Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

GLPG Company Calendar

Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLPG
CUSIP
N/A
CIK
1421876
Web
www.glpg.com
Phone
(321) 534-2900
Fax
321-534-2901
Employees
1,309
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.83
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+39.3%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-122,130,000.00
Net Margins
1.13%
Pretax Margin
2.34%
Return on Equity
0.25%
Return on Assets
0.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.38
Quick Ratio
8.34

Sales & Book Value

Annual Sales
$573.66 million
Price / Sales
4.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$41.16 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
65,836,000
Free Float
63,920,000
Market Cap
$2.64 billion
Optionable
Optionable
Beta
0.47

Key Executives

  • Mr. Bart Filius M.B.A. (Age 52)
    MBA, Pres, COO & Member of Management Board
    Comp: $814.35k
  • Dr. Andre Hoekema Ph.D. (Age 65)
    Chief Bus. Officer & Member of Management Board
    Comp: $573.78k
  • Dr. Walid Abi-Saab (Age 57)
    Chief Medical Officer & Member of Management Board
    Comp: $677.78k
  • Mr. Michele Manto M.B.A.
    Chief Commercial Officer & Member of Management Board
  • Dr. Paulus A. Stoffels M.D. (Age 60)
    Ph.D., CEO, Chairman & Member of Management Board
  • Ms. Elizabeth Goodwin
    VP of Investor Relations
  • Ms. Sofie Van Gijsel
    Head of Investor Relations
  • Marieke Vermeersch
    Head of Corp. Communication
  • John Montana
    Managing Director of Argenta
  • Ms. Chantal Tasset
    Head of Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GLPG Stock - Frequently Asked Questions

Should I buy or sell Galapagos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings or view top-rated stocks.

What is Galapagos' stock price forecast for 2023?

9 analysts have issued 12 month price targets for Galapagos' shares. Their GLPG share price forecasts range from $40.00 to $70.00. On average, they anticipate the company's share price to reach $55.83 in the next year. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts.

How have GLPG shares performed in 2022?

Galapagos' stock was trading at $55.13 at the beginning of 2022. Since then, GLPG shares have decreased by 27.3% and is now trading at $40.07.
View the best growth stocks for 2022 here.

When is Galapagos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our GLPG earnings forecast.

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.73%), Prosight Management LP (0.62%), Finepoint Capital LP (0.58%), Renaissance Technologies LLC (0.45%), Tang Capital Management LLC (0.34%) and Optiver Holding B.V. (0.00%).

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $40.07.

How much money does Galapagos make?

Galapagos (NASDAQ:GLPG) has a market capitalization of $2.64 billion and generates $573.66 million in revenue each year.

How many employees does Galapagos have?

The company employs 1,309 workers across the globe.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901.

This page (NASDAQ:GLPG) was last updated on 12/2/2022 by MarketBeat.com Staff